AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
brivaracetam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| amide type nootrope agents, piracetam derivatives | 5068 | 357336-20-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.56 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.75 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.83 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 8.98 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 700 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 100 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,STK33,SYK,TEK | 30 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 2016 | FDA | UCB INC | |
| Jan. 14, 2016 | EMA | UCB Pharma SA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 842.73 | 32.79 | 328 | 5481 | 152301 | 90470337 |
| Multiple-drug resistance | 358.09 | 32.79 | 86 | 5723 | 7690 | 90614948 |
| Generalised tonic-clonic seizure | 271.66 | 32.79 | 97 | 5712 | 34806 | 90587832 |
| Status epilepticus | 187.56 | 32.79 | 63 | 5746 | 18811 | 90603827 |
| Off label use | 182.92 | 32.79 | 282 | 5527 | 1101970 | 89520668 |
| Partial seizures | 179.85 | 32.79 | 49 | 5760 | 7211 | 90615427 |
| Maternal exposure before pregnancy | 154.58 | 32.79 | 48 | 5761 | 11165 | 90611473 |
| Maternal exposure during pregnancy | 149.59 | 32.79 | 147 | 5662 | 359916 | 90262722 |
| Aggression | 130.95 | 32.79 | 53 | 5756 | 26615 | 90596023 |
| Irritability | 128.88 | 32.79 | 57 | 5752 | 35605 | 90587033 |
| Petit mal epilepsy | 125.29 | 32.79 | 34 | 5775 | 4924 | 90617714 |
| Suicidal ideation | 115.62 | 32.79 | 67 | 5742 | 73788 | 90548850 |
| Overdose | 115.25 | 32.79 | 89 | 5720 | 157620 | 90465018 |
| Behaviour disorder | 108.82 | 32.79 | 30 | 5779 | 4605 | 90618033 |
| Mood swings | 97.70 | 32.79 | 40 | 5769 | 20662 | 90601976 |
| Drug ineffective | 96.82 | 32.79 | 247 | 5562 | 1384051 | 89238587 |
| Anticonvulsant drug level increased | 78.81 | 32.79 | 19 | 5790 | 1717 | 90620921 |
| Epilepsy | 70.22 | 32.79 | 51 | 5758 | 82155 | 90540483 |
| Sudden unexplained death in epilepsy | 67.76 | 32.79 | 13 | 5796 | 395 | 90622243 |
| Product availability issue | 66.78 | 32.79 | 23 | 5786 | 7381 | 90615257 |
| Cognitive disorder | 61.41 | 32.79 | 44 | 5765 | 69363 | 90553275 |
| Somnolence | 57.74 | 32.79 | 69 | 5740 | 209015 | 90413623 |
| Abortion spontaneous | 56.58 | 32.79 | 38 | 5771 | 54018 | 90568620 |
| Depression | 56.37 | 32.79 | 82 | 5727 | 300519 | 90322119 |
| Seizure cluster | 56.02 | 32.79 | 11 | 5798 | 378 | 90622260 |
| JC polyomavirus test | 55.61 | 32.79 | 8 | 5801 | 36 | 90622602 |
| Mental disorder | 55.02 | 32.79 | 31 | 5778 | 32287 | 90590351 |
| Anger | 52.99 | 32.79 | 23 | 5786 | 13697 | 90608941 |
| Partial seizures with secondary generalisation | 47.69 | 32.79 | 10 | 5799 | 479 | 90622159 |
| Dizziness | 42.61 | 32.79 | 107 | 5702 | 589177 | 90033461 |
| Ataxia | 41.07 | 32.79 | 21 | 5788 | 18021 | 90604617 |
| Drug ineffective for unapproved indication | 40.88 | 32.79 | 34 | 5775 | 66610 | 90556028 |
| Postictal paralysis | 40.57 | 32.79 | 8 | 5801 | 281 | 90622357 |
| Gaze palsy | 40.27 | 32.79 | 11 | 5798 | 1630 | 90621008 |
| Focal dyscognitive seizures | 37.26 | 32.79 | 12 | 5797 | 3132 | 90619506 |
| Hallucination | 35.05 | 32.79 | 31 | 5778 | 65928 | 90556710 |
| Change in seizure presentation | 34.85 | 32.79 | 8 | 5801 | 584 | 90622054 |
| Aura | 33.82 | 32.79 | 9 | 5800 | 1208 | 90621430 |
| Hallucination, olfactory | 33.77 | 32.79 | 7 | 5802 | 317 | 90622321 |
| Psychogenic seizure | 33.63 | 32.79 | 10 | 5799 | 2006 | 90620632 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 634.02 | 38.42 | 293 | 4423 | 120268 | 42496351 |
| Multiple-drug resistance | 288.88 | 38.42 | 80 | 4636 | 7242 | 42609377 |
| Status epilepticus | 202.72 | 38.42 | 73 | 4643 | 15505 | 42601114 |
| Drug ineffective | 154.50 | 38.42 | 259 | 4457 | 629938 | 41986681 |
| Generalised tonic-clonic seizure | 133.84 | 38.42 | 63 | 4653 | 26316 | 42590303 |
| Off label use | 122.31 | 38.42 | 236 | 4480 | 638099 | 41978520 |
| Partial seizures | 121.59 | 38.42 | 39 | 4677 | 5820 | 42610799 |
| Aggression | 119.01 | 38.42 | 69 | 4647 | 44094 | 42572525 |
| Irritability | 97.79 | 38.42 | 52 | 4664 | 28076 | 42588543 |
| Focal dyscognitive seizures | 96.13 | 38.42 | 24 | 4692 | 1443 | 42615176 |
| Aura | 95.11 | 38.42 | 19 | 4697 | 406 | 42616213 |
| Somnolence | 91.02 | 38.42 | 94 | 4622 | 141011 | 42475608 |
| Behaviour disorder | 84.01 | 38.42 | 31 | 4685 | 7023 | 42609596 |
| Overdose | 82.45 | 38.42 | 78 | 4638 | 105186 | 42511433 |
| Epilepsy | 70.71 | 38.42 | 41 | 4675 | 26130 | 42590489 |
| Drug level fluctuating | 64.66 | 38.42 | 15 | 4701 | 659 | 42615960 |
| Hyperammonaemic encephalopathy | 64.00 | 38.42 | 20 | 4696 | 2738 | 42613881 |
| Petit mal epilepsy | 62.42 | 38.42 | 21 | 4695 | 3629 | 42612990 |
| Anger | 59.59 | 38.42 | 29 | 4687 | 12989 | 42603630 |
| Memory impairment | 59.09 | 38.42 | 47 | 4669 | 50175 | 42566444 |
| Partial seizures with secondary generalisation | 54.57 | 38.42 | 12 | 4704 | 413 | 42616206 |
| Suicidal ideation | 54.37 | 38.42 | 44 | 4672 | 48117 | 42568502 |
| Psychogenic seizure | 53.24 | 38.42 | 12 | 4704 | 463 | 42616156 |
| Product availability issue | 51.19 | 38.42 | 18 | 4698 | 3549 | 42613070 |
| Affective disorder | 48.94 | 38.42 | 20 | 4696 | 5940 | 42610679 |
| Hydrocephalus | 48.56 | 38.42 | 20 | 4696 | 6058 | 42610561 |
| Tonic convulsion | 46.88 | 38.42 | 14 | 4702 | 1645 | 42614974 |
| Salivary hypersecretion | 45.98 | 38.42 | 23 | 4693 | 10920 | 42605699 |
| Therapy interrupted | 45.06 | 38.42 | 29 | 4687 | 22221 | 42594398 |
| Myoclonus | 44.13 | 38.42 | 26 | 4690 | 17039 | 42599580 |
| Prescribed overdose | 39.60 | 38.42 | 22 | 4694 | 12905 | 42603714 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 1000.39 | 31.12 | 431 | 7857 | 220754 | 110360257 |
| Multiple-drug resistance | 640.58 | 31.12 | 157 | 8131 | 13078 | 110567933 |
| Generalised tonic-clonic seizure | 310.65 | 31.12 | 126 | 8162 | 54554 | 110526457 |
| Status epilepticus | 281.10 | 31.12 | 101 | 8187 | 31470 | 110549541 |
| Partial seizures | 231.06 | 31.12 | 68 | 8220 | 11281 | 110569730 |
| Drug ineffective | 211.04 | 31.12 | 392 | 7896 | 1520148 | 109060863 |
| Off label use | 211.01 | 31.12 | 389 | 7899 | 1499796 | 109081215 |
| Petit mal epilepsy | 174.81 | 31.12 | 50 | 8238 | 7497 | 110573514 |
| Behaviour disorder | 166.94 | 31.12 | 51 | 8237 | 9596 | 110571415 |
| Aggression | 164.90 | 31.12 | 83 | 8205 | 59127 | 110521884 |
| Irritability | 150.92 | 31.12 | 73 | 8215 | 47736 | 110533275 |
| Somnolence | 142.23 | 31.12 | 141 | 8147 | 297308 | 110283703 |
| Epilepsy | 138.96 | 31.12 | 89 | 8199 | 100120 | 110480891 |
| Overdose | 123.28 | 31.12 | 117 | 8171 | 233677 | 110347334 |
| Suicidal ideation | 121.80 | 31.12 | 80 | 8208 | 93857 | 110487154 |
| Partial seizures with secondary generalisation | 118.20 | 31.12 | 24 | 8264 | 835 | 110580176 |
| Mood swings | 117.27 | 31.12 | 49 | 8239 | 22763 | 110558248 |
| Focal dyscognitive seizures | 109.67 | 31.12 | 30 | 8258 | 3819 | 110577192 |
| Maternal exposure before pregnancy | 103.06 | 31.12 | 33 | 8255 | 7232 | 110573779 |
| Anger | 88.29 | 31.12 | 38 | 8250 | 18969 | 110562042 |
| Aura | 84.06 | 31.12 | 19 | 8269 | 1105 | 110579906 |
| Seizure cluster | 84.04 | 31.12 | 18 | 8270 | 815 | 110580196 |
| Sudden unexplained death in epilepsy | 73.01 | 31.12 | 16 | 8272 | 807 | 110580204 |
| Myoclonic epilepsy | 67.59 | 31.12 | 19 | 8269 | 2672 | 110578339 |
| Anticonvulsant drug level increased | 66.46 | 31.12 | 19 | 8269 | 2839 | 110578172 |
| Product availability issue | 65.51 | 31.12 | 24 | 8264 | 7866 | 110573145 |
| Hyperammonaemic encephalopathy | 62.23 | 31.12 | 21 | 8267 | 5413 | 110575598 |
| Myoclonus | 60.28 | 31.12 | 35 | 8253 | 32963 | 110548048 |
| Mental disorder | 60.10 | 31.12 | 37 | 8251 | 38754 | 110542257 |
| Drug resistance | 58.77 | 31.12 | 42 | 8246 | 56332 | 110524679 |
| Ataxia | 57.84 | 31.12 | 33 | 8255 | 30075 | 110550936 |
| Diplopia | 57.48 | 31.12 | 37 | 8251 | 41857 | 110539154 |
| Atonic seizures | 57.31 | 31.12 | 14 | 8274 | 1140 | 110579871 |
| Psychogenic seizure | 56.24 | 31.12 | 16 | 8272 | 2348 | 110578663 |
| Abnormal behaviour | 54.85 | 31.12 | 35 | 8253 | 39004 | 110542007 |
| JC polyomavirus test | 54.00 | 31.12 | 8 | 8280 | 38 | 110580973 |
| Tonic convulsion | 52.10 | 31.12 | 16 | 8272 | 3058 | 110577953 |
| Drug ineffective for unapproved indication | 51.31 | 31.12 | 50 | 8238 | 102788 | 110478223 |
| Maternal exposure during pregnancy | 51.05 | 31.12 | 78 | 8210 | 254805 | 110326206 |
| Erectile dysfunction | 48.65 | 31.12 | 25 | 8263 | 18531 | 110562480 |
| Salivary hypersecretion | 47.21 | 31.12 | 24 | 8264 | 17397 | 110563614 |
| Vagal nerve stimulator implantation | 46.59 | 31.12 | 9 | 8279 | 241 | 110580770 |
| Gaze palsy | 46.37 | 31.12 | 15 | 8273 | 3392 | 110577619 |
| Hydrocephalus | 45.75 | 31.12 | 20 | 8268 | 10355 | 110570656 |
| Postictal paralysis | 43.75 | 31.12 | 10 | 8278 | 611 | 110580400 |
| Dizziness | 41.92 | 31.12 | 131 | 8157 | 698062 | 109882949 |
| Depression | 41.02 | 31.12 | 80 | 8208 | 317255 | 110263756 |
| Psychotic disorder | 39.90 | 31.12 | 32 | 8256 | 50905 | 110530106 |
| Brain operation | 39.85 | 31.12 | 10 | 8278 | 910 | 110580101 |
| Dyspnoea | 39.27 | 31.12 | 17 | 8271 | 1106855 | 109474156 |
| Balance disorder | 39.24 | 31.12 | 46 | 8242 | 116514 | 110464497 |
| Cognitive disorder | 38.95 | 31.12 | 40 | 8248 | 87471 | 110493540 |
| Arthralgia | 38.94 | 31.12 | 6 | 8282 | 779626 | 109801385 |
| Pain | 38.36 | 31.12 | 12 | 8276 | 954943 | 109626068 |
| Memory impairment | 37.63 | 31.12 | 59 | 8229 | 196885 | 110384126 |
| Change in seizure presentation | 35.80 | 31.12 | 9 | 8279 | 825 | 110580186 |
| Simple partial seizures | 33.86 | 31.12 | 9 | 8279 | 1027 | 110579984 |
| Psychiatric symptom | 31.88 | 31.12 | 15 | 8273 | 9198 | 110571813 |
| Autoimmune aplastic anaemia | 31.22 | 31.12 | 4 | 8284 | 4 | 110581007 |
FDA Adverse Event Reporting System (Pediatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cardiac septal defect | 37.58 | 21.83 | 5 | 9 | 5 | 113934 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N03AX23 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002491 | Central Nervous System Agents |
| FDA MoA | N0000192345 | Epoxide Hydrolase Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
Related Drugs by ATC class:
N03AX Other antiepileptics 18 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Partial seizure | indication | 29753000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.83 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG | BRIVIACT | UCB INC | N205836 | May 12, 2016 | RX | TABLET | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| 10MG | BRIVIACT | UCB INC | N205836 | May 12, 2016 | RX | TABLET | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| 25MG | BRIVIACT | UCB INC | N205836 | May 12, 2016 | RX | TABLET | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| 50MG | BRIVIACT | UCB INC | N205836 | May 12, 2016 | RX | TABLET | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| 75MG | BRIVIACT | UCB INC | N205836 | May 12, 2016 | RX | TABLET | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| 50MG/5ML (10MG/ML) | BRIVIACT | UCB INC | N205837 | May 12, 2016 | RX | SOLUTION | INTRAVENOUS | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY |
| 50MG/5ML (10MG/ML) | BRIVIACT | UCB INC | N205837 | May 12, 2016 | RX | SOLUTION | INTRAVENOUS | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY |
| 10MG/ML | BRIVIACT | UCB INC | N205838 | May 12, 2016 | RX | SOLUTION | ORAL | 6911461 | Feb. 21, 2026 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicle glycoprotein 2A | Transporter | MODULATOR | Ki | 7.10 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Synaptic vesicle glycoprotein 2A | Transporter | INHIBITOR | IC50 | 7 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| U863JGG2IA | UNII |
| D08879 | KEGG_DRUG |
| 4035741 | VANDF |
| C1699861 | UMLSCUI |
| CHEBI:133013 | CHEBI |
| CHEMBL607400 | ChEMBL_ID |
| 9837243 | PUBCHEM_CID |
| DB05541 | DRUGBANK_ID |
| 8642 | INN_ID |
| C482793 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9041 | IUPHAR_LIGAND_ID |
| 1739745 | RXNORM |
| 238946 | MMSL |
| 31471 | MMSL |
| 401367 | MMSL |
| d08414 | MMSL |
| 016704 | NDDF |
| 420813001 | SNOMEDCT_US |
| 421052000 | SNOMEDCT_US |
| VLX | PDB_CHEM_ID |
| U863JGG2IA | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1074 | SOLUTION | 10 mg | ORAL | ANDA | 36 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1075 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 36 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-420 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 32 sections |
| BRIVARACETAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-370 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-556 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 36 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-557 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 36 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-558 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 36 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-559 | TABLET, FILM COATED | 75 mg | ORAL | ANDA | 36 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-560 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-370 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-470 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-570 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-670 | TABLET, FILM COATED | 75 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-770 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-870 | SOLUTION | 10 mg | ORAL | NDA | 36 sections |
| Briviact | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50474-970 | INJECTION, SUSPENSION | 50 mg | INTRAVENOUS | NDA | 36 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4723 | TABLET | 10 mg | ORAL | ANDA | 32 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4724 | TABLET | 25 mg | ORAL | ANDA | 32 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4725 | TABLET | 50 mg | ORAL | ANDA | 32 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4726 | TABLET | 75 mg | ORAL | ANDA | 32 sections |
| Brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4727 | TABLET | 100 mg | ORAL | ANDA | 32 sections |
| Brivaracetam Oral Solution | Human Prescription Drug Label | 1 | 67877-904 | SOLUTION | 10 mg | ORAL | ANDA | 30 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1584 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 31 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1585 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 31 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1586 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 31 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1587 | TABLET, FILM COATED | 75 mg | ORAL | ANDA | 31 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1588 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 31 sections |
| BRIVARACETAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70748-411 | SOLUTION | 10 mg | ORAL | ANDA | 30 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1754 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 2 sections |
| brivaracetam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1755 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 2 sections |